People with keratoconus have a new treatment option. The U.S. Food and Drug Administration (FDA) has approved corneal collagen cross-linking (CXL) for progressive thinning and distortion of the cornea.
The treatment uses a special laser and eye drops to promote “cross-linking,” or strengthening, of collagen fibers in the cornea.
CXL has been in wide use outside the United States for about a decade. Based on three year-long studies, the FDA approved the new treatment for keratoconus and other types of corneal ectasia. Corneal ectasia is the general name for conditions in which the cornea gets thinner and changes shape.
The cornea is the clear front window of the eye where light enters. It helps you see by focusing the light.